CINXE.COM

<!DOCTYPE html> <html class="no-js" lang="en" prefix="og: https://ogp.me/ns#"> <head> <script src="https://sp-library.prod.sp.aws.clarivate.net/oti/latest/index.umd.js"></script> <link href="https://www.bioworld.com/authors/64-lee-landenberger" rel="canonical"> <meta charset="utf-8"> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="op4UzG3EEJgX0DX3WqdkM1B3ifwdgn3HAn6OELl4eEeFzf5MHxvxsC0LmjG9hikoA9GaH0thb1OUZm5LQ/QjkQ==" /> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <meta name="timestamp" value="2024-11-27 10:49:11 -0500"> <meta name="description" content="BioWorld - Lee Landenberger" /> <meta name="keywords" content="Lee Landenberger" /> <link rel="alternate" type="application/xml" title="BioWorld RSS Feed" href="https://www.bioworld.com/rss/articles" /> <meta property="og:title" content="Lee Landenberger" /> <meta property="og:description" content="Lee Landenberger" /> <meta property="og:url" content="https://www.bioworld.com/authors/64-lee-landenberger" /> <meta property="og:type" content="Author" /> <meta name="twitter:title" content="Lee Landenberger" /> <meta name="twitter:description" content="Lee Landenberger" /> <meta name="twitter:card" content="summary" /> <meta property="og:title" /> <meta property="og:description" /> <meta property="og:url" /> <meta property="og:type" content="Website" /> <meta content="false" name="has-log-view" /> <title>Lee Landenberger | BioWorld</title> <link rel="stylesheet" media="screen" href="/stylesheets/application.css?v=1732722551" /> <script src="/javascripts/jade.default.min.js?v=1732722551"></script> <script src="/javascripts/application.js?v=1732722551"></script>  <script>var dataLayer = window.dataLayer || [];</script> <script>let snowplowData = {"event":"SnowplowStructuredEvent","product":""}; fetch('/user/snowplow', { method: 'GET', headers: { 'Content-Type': 'application/json' } }) .then(response => { if (!response.ok) { throw new Error(`HTTP error! status: ${response.status}`); } return response.json(); }) .then(data => { const evt = Object.assign({}, snowplowData, data); console.info('Snowplow Data:', evt); // Handle the fetched data dataLayer.push(evt); }) .catch(error => { console.error('Error fetching snowplow data:', error); // Handle any errors });</script><script>dataLayer.push({"id":64,"title":"Lee Landenberger","page_type":["authors"],"date_posted":"07/19/2019","gated":false,"registered":false});</script> <script>typeof window.dataLayer[0] === 'object' && !('page_type' in window.dataLayer[0]) && window.dataLayer.push({"id":64,"title":"Lee Landenberger","page_type":["authors"],"date_posted":"07/19/2019","gated":false,"registered":false});</script>   <script> //<![CDATA[ (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5ZV86V9'); //]]> </script>  <script> window.epub = window.epub || {}; window.epub['AD_HISTORY_ENABLED'] = false; </script> <link rel="apple-touch-icon" sizes="180x180" href="/icons/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16x16.png"> <link rel="manifest" href="/icons/site.webmanifest"> <link rel="mask-icon" href="/icons/safari-pinned-tab.svg" color="#5bbad5"> <link rel="shortcut icon" href="/icons/favicon.ico"> <meta name="msapplication-TileColor" content="#00aba9"> <meta name="msapplication-config" content="/icons/browserconfig.xml"> <meta name="theme-color" content="#ffffff"><script> var googletag = { cmd: [] }; var targeting = window.targeting = {"id":"64","tags":[],"taxonomy":[],"taxonomy_id":[],"sponsored":"false","page_type":["authors"],"keyword":[],"reg_user":"false","page_name":"64-lee-landenberger","search_terms":"","url":"/authors/64-lee-landenberger","site_env":"production"}; </script> <script>if (typeof Oti !== "undefined" && typeof Oti.OtiService !== "undefined") { $.post('/user/pendo', function(data) { const pendoVisitor = data.visitor const pendoAccount = Object.keys(pendoVisitor).length > 0 ? data.account : '' const anomID = 'VISITOR-UNIQUE-ID' const pendovistorID = (pendoVisitor && Object.keys(pendoVisitor).length > 0 && pendoVisitor.id) ? `${pendoVisitor.id}` : anomID; const otiService = new Oti.OtiService({ ot_key: "603e2c5b-3a1d-4eac-a9c9-fb20c3b528f2", prod_domain: "www.bioworld-stage.epublishing.com", pendo_key: "34b78be2-b210-4df9-7f2b-7552afe5341c", pendo_details: { visitor: { id: pendovistorID, firstName: pendoVisitor.first_name, lastName: pendoVisitor.last_name, email: pendoVisitor.email, country: pendoVisitor.country, company: pendoVisitor.company, last_login: pendoVisitor.last_login, opted_out_at: pendoVisitor.opted_out_at, }, account: { id: pendoAccount } }, pendo_visitor_payload: [{ visitorId: pendovistorID, values: { firstName: pendoVisitor.first_name, lastName: pendoVisitor.last_name, email: pendoVisitor.email, country: pendoVisitor.country, company: pendoVisitor.company, last_login: pendoVisitor.last_login, opted_out_at: pendoVisitor.opted_out_at, } }], pendo_visitor_url: '/ui/pendoapi/agent/value?create=true', pendo_dnp_url: `/ui/pendoapi/pendo/value/${pendovistorID}/donotprocess`, pendo_metadata_url: `/ui/pendoapi/custom/value/${pendovistorID}/bioworld_targetingcookies`, }); otiService.initialize(); }); }</script> <link rel="preload" as="script" href="https://cdn.ampproject.org/v0.js"> <script async src="https://cdn.ampproject.org/v0.js"></script>  <style amp-custom>/* Add your styles here */</style> <style amp-boilerplate>body{-webkit-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-moz-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-ms-animation:-amp-start 8s steps(1,end) 0s 1 normal both;animation:-amp-start 8s steps(1,end) 0s 1 normal both}@-webkit-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-moz-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-ms-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-o-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}</style><noscript><style amp-boilerplate>body{-webkit-animation:none;-moz-animation:none;-ms-animation:none;animation:none}</style></noscript> <link rel="canonical" href="."> <script async custom-element="amp-iframe" src="https://cdn.ampproject.org/v0/amp-iframe-0.1.js"></script> <script>var _document$querySelect, _document$querySelect2; var $hasLogViewMeta = (_document$querySelect = document.querySelector('meta[name=has-log-view]')) === null || _document$querySelect === void 0 ? void 0 : _document$querySelect.getAttribute('content'); var $logViewUrlMeta = (_document$querySelect2 = document.querySelector('meta[name=log-view-url]')) === null || _document$querySelect2 === void 0 ? void 0 : _document$querySelect2.getAttribute('content'); if ($hasLogViewMeta === 'true') { var baseLogUrl = typeof $logViewUrlMeta === "undefined" ? window.location.pathname : $logViewUrlMeta; var logUrl = baseLogUrl + '/log_view' + window.location.search; if (typeof navigator.sendBeacon === 'function') { navigator.sendBeacon(logUrl); } else { // Gotta love IE var request = new XMLHttpRequest(); request.open('POST', logUrl, true); request.setRequestHeader('Content-Type', 'application/x-www-form-urlencoded; charset=UTF-8'); request.send(); } }</script> </head> <body data-controller="authors" data-action="show" data-prestitial-ad="false" data-poststitial-ad="false" data-news-services="">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5ZV86V9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <div class="document mmenu-placeholder"><header class="main-header"><div class="main-header__top"><h1> <a href="/" class="main-header__logo" data-eventaction="logo-link" data-eventcategory="click" data-eventlabel="link to homepage" data-eventname="logo-link"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 201 36" height="36" fill="none" preservAspectRatio="xMidYMid meet"> <title>BioWorld. Link to homepage.</title> <path fill="#000" d="M17.7999 16.5745v.1066c3.8891 1.5805 6.2511 4.4219 6.2511 8.3111 0 5.3809-3.9958 9.6608-11.0993 9.6608H1V1.01776h10.8506c6.9082 0 10.3712 4.27988 10.3712 8.59527 0 2.93017-1.4385 5.57627-4.4219 6.96147zM7.67732 6.68283v7.49427H11.087c2.3975 0 4.3687-1.2076 4.3687-3.8004 0-2.59283-2.06-3.69387-4.3687-3.69387H7.67732zm0 22.34057h3.46298c4.0313 0 5.9492-1.8646 5.9492-4.6173 0-2.8414-2.3619-4.2798-5.6118-4.2798H7.67732v8.8971zM35.239 34.6352h-6.2333v-16.711h-3.0723V12.632h9.3056v22.0032zM31.8293 1.01776c2.2554 0 4.0313 1.82916 4.0313 4.03125 0 2.25538-1.7759 3.97798-4.0313 3.97798-2.2021 0-3.9957-1.7226-3.9957-3.97798.0178-2.20209 1.7936-4.03125 3.9957-4.03125zM39.217 23.6425c0-6.7128 5.2389-11.5787 11.7564-11.5787 6.5175 0 11.7563 4.8481 11.7563 11.5787s-5.2388 11.5788-11.7563 11.5788c-6.5175 0-11.7564-4.8659-11.7564-11.5788zm6.2511 0c0 3.4097 2.2554 6.0025 5.523 6.0025 3.2144 0 5.4697-2.5928 5.4697-6.0025 0-3.463-2.2553-6.0025-5.4697-6.0025-3.2676 0-5.523 2.5395-5.523 6.0025zM88.7286 1.01776L95.1573 25.081h.0533l5.3814-24.06324h6.819L99.2064 34.6352h-7.7251l-6.3399-24.152-6.1979 24.152h-7.7251L62.9073 1.01776h7.2101L75.303 25.081h.0532l6.4287-24.06324h6.9437zM106.701 23.6425c0-6.7128 5.238-11.5787 11.756-11.5787 6.535 0 11.756 4.8481 11.756 11.5787s-5.239 11.5788-11.756 11.5788c-6.535-.0178-11.756-4.8659-11.756-11.5788zm6.233 0c0 3.4097 2.255 6.0025 5.523 6.0025 3.214 0 5.47-2.5928 5.47-6.0025 0-3.463-2.256-6.0025-5.47-6.0025-3.268 0-5.523 2.5395-5.523 6.0025zm34.772-4.8481h-2.646c-3.161 0-4.618 1.4917-4.618 5.3276v10.5132h-6.233V12.632h6.056v3.4985c.87-2.3441 2.983-3.8004 5.718-3.8004.586 0 1.154.0533 1.723.1954v6.2689zm9.696 15.8408h-6.198V1.01776h6.198V34.6352zm21.559-2.7881c-1.101 1.8292-3.694 3.3564-6.872 3.3564-6.056 0-10.656-4.8481-10.656-11.5787s4.564-11.5788 10.62-11.5788c3.357 0 5.914 1.545 7.015 3.4097 0-.7281-.089-2.5395-.089-4.1733V1h6.233v33.6175h-6.233v-2.7704h-.018zm-11.081-8.2046c0 3.3564 2.308 6.0558 5.612 6.0558 3.303 0 5.611-2.6994 5.611-6.0558 0-3.4097-2.308-6.0025-5.611-6.0025-3.304 0-5.612 2.5928-5.612 6.0025zM191.801 2.58054h2.06V1.01776h-5.772v1.56278h2.043V6.8249h1.669V2.58054zM201 6.8249V1.01776h-2.184l-1.119 2.84141-1.101-2.84141h-2.22V6.8249h1.652V3.13106l1.101 2.66382h1.065l1.101-2.68158v3.7116H201z"/> </svg> </a> </h1><a href='https://clarivate.com/cortellis/' target="_blank" class="main-header__logo -clarivate"> <img src="/images/Cortellis_Flagship_Logo.png" alt="Clarivate" title="Powering insights from Cortellis. Link to Cortellis page on Clarivate website."> </a></div><div class="main-nav-container"><div class="main-nav-container__wrapper"><nav id="main-nav" class="main-nav main-nav--horizontal"><div class="navigation"><ul class="main-nav-level1__items"><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld|/topics/84-bioworld" href="/topics/84-bioworld">BioWorld</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Asia|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">BioWorld Asia</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Science|/topics/520-bioworld-science" href="/topics/520-bioworld-science">BioWorld Science</a></li><li class="main-nav-level1__item"><a class="main-nav__link -has-children" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Data Snapshots|/snapshots" href="/snapshots">Data Snapshots</a><ul class="main-nav-level2__items"><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld|/snapshots" href="/snapshots">BioWorld</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech|/medtech_snapshots" href="/medtech_snapshots">BioWorld MedTech</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li></ul></li><li class="main-nav-level1__item"><a class="main-nav__link -has-children" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Special reports|/special_reports" href="/special_reports">Special reports</a><ul class="main-nav-level2__items"><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Women's health|/womens_health" href="/womens_health">Women's health</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="China's GLP-1 landscape|/China_GLP-1" href="/China_GLP-1">China's GLP-1 landscape</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="PFA re-energizes afib market|https://www.bioworld.com/articles/711618-pulsed-field-ablation-re-energizes-the-atrial-fibrillation-market" href="https://www.bioworld.com/articles/711618-pulsed-field-ablation-re-energizes-the-atrial-fibrillation-market">PFA re-energizes afib market</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="China CAR T|/China_CAR_T" href="/China_CAR_T">China CAR T</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Alzheimer's disease|/Alzheimers" href="/Alzheimers">Alzheimer's disease</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Israel|/israel" href="/israel">Israel</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Rise of obesity|/rise_of_obesity" href="/rise_of_obesity">Rise of obesity</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Radiopharmaceuticals|/radiopharmaceuticals" href="/radiopharmaceuticals">Radiopharmaceuticals</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Biosimilars|/biosimilars" href="/biosimilars">Biosimilars</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Aging|/aging" href="/aging">Aging</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="IVDs on the rise|/IVDs-2021" href="/IVDs-2021">IVDs on the rise</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Coronavirus|/articles/topic/517" href="/articles/topic/517">Coronavirus</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Artificial intelligence|/AI_series" href="/AI_series">Artificial intelligence</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Premium reports|/premium-reports" href="/premium-reports">Premium reports</a><ul class="main-nav-level3__items"><li class="main-nav-level3__item"><a data-eventcategory="click" data-eventaction="-link" data-eventlabel="BioWorld Financings Reports|/bioworld-financings-reports" href="/bioworld-financings-reports">BioWorld Financings Reports</a></li><li class="main-nav-level3__item"><a data-eventcategory="click" data-eventaction="-link" data-eventlabel="Disease Incidence & Prevalence Summaries|https://clarivate.com/products/research-reports/disease-incidence-and-prevalence-summaries/" target="_blank" href="https://clarivate.com/products/research-reports/disease-incidence-and-prevalence-summaries/">Disease Incidence & Prevalence Summaries</a></li></ul></li></ul></li></ul></div></nav><div class="main-nav-container__mobile-nav"><a class="hamburger-nav-link" href="#" id="hamburger-nav-link"></a><h1> <a href="/" class="main-header__logo" data-eventaction="logo-link" data-eventcategory="click" data-eventlabel="link to homepage" data-eventname="logo-link"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 201 36" height="36" fill="none" preservAspectRatio="xMidYMid meet"> <title>BioWorld. Link to homepage.</title> <path fill="#000" d="M17.7999 16.5745v.1066c3.8891 1.5805 6.2511 4.4219 6.2511 8.3111 0 5.3809-3.9958 9.6608-11.0993 9.6608H1V1.01776h10.8506c6.9082 0 10.3712 4.27988 10.3712 8.59527 0 2.93017-1.4385 5.57627-4.4219 6.96147zM7.67732 6.68283v7.49427H11.087c2.3975 0 4.3687-1.2076 4.3687-3.8004 0-2.59283-2.06-3.69387-4.3687-3.69387H7.67732zm0 22.34057h3.46298c4.0313 0 5.9492-1.8646 5.9492-4.6173 0-2.8414-2.3619-4.2798-5.6118-4.2798H7.67732v8.8971zM35.239 34.6352h-6.2333v-16.711h-3.0723V12.632h9.3056v22.0032zM31.8293 1.01776c2.2554 0 4.0313 1.82916 4.0313 4.03125 0 2.25538-1.7759 3.97798-4.0313 3.97798-2.2021 0-3.9957-1.7226-3.9957-3.97798.0178-2.20209 1.7936-4.03125 3.9957-4.03125zM39.217 23.6425c0-6.7128 5.2389-11.5787 11.7564-11.5787 6.5175 0 11.7563 4.8481 11.7563 11.5787s-5.2388 11.5788-11.7563 11.5788c-6.5175 0-11.7564-4.8659-11.7564-11.5788zm6.2511 0c0 3.4097 2.2554 6.0025 5.523 6.0025 3.2144 0 5.4697-2.5928 5.4697-6.0025 0-3.463-2.2553-6.0025-5.4697-6.0025-3.2676 0-5.523 2.5395-5.523 6.0025zM88.7286 1.01776L95.1573 25.081h.0533l5.3814-24.06324h6.819L99.2064 34.6352h-7.7251l-6.3399-24.152-6.1979 24.152h-7.7251L62.9073 1.01776h7.2101L75.303 25.081h.0532l6.4287-24.06324h6.9437zM106.701 23.6425c0-6.7128 5.238-11.5787 11.756-11.5787 6.535 0 11.756 4.8481 11.756 11.5787s-5.239 11.5788-11.756 11.5788c-6.535-.0178-11.756-4.8659-11.756-11.5788zm6.233 0c0 3.4097 2.255 6.0025 5.523 6.0025 3.214 0 5.47-2.5928 5.47-6.0025 0-3.463-2.256-6.0025-5.47-6.0025-3.268 0-5.523 2.5395-5.523 6.0025zm34.772-4.8481h-2.646c-3.161 0-4.618 1.4917-4.618 5.3276v10.5132h-6.233V12.632h6.056v3.4985c.87-2.3441 2.983-3.8004 5.718-3.8004.586 0 1.154.0533 1.723.1954v6.2689zm9.696 15.8408h-6.198V1.01776h6.198V34.6352zm21.559-2.7881c-1.101 1.8292-3.694 3.3564-6.872 3.3564-6.056 0-10.656-4.8481-10.656-11.5787s4.564-11.5788 10.62-11.5788c3.357 0 5.914 1.545 7.015 3.4097 0-.7281-.089-2.5395-.089-4.1733V1h6.233v33.6175h-6.233v-2.7704h-.018zm-11.081-8.2046c0 3.3564 2.308 6.0558 5.612 6.0558 3.303 0 5.611-2.6994 5.611-6.0558 0-3.4097-2.308-6.0025-5.611-6.0025-3.304 0-5.612 2.5928-5.612 6.0025zM191.801 2.58054h2.06V1.01776h-5.772v1.56278h2.043V6.8249h1.669V2.58054zM201 6.8249V1.01776h-2.184l-1.119 2.84141-1.101-2.84141h-2.22V6.8249h1.652V3.13106l1.101 2.66382h1.065l1.101-2.68158v3.7116H201z"/> </svg> </a> </h1><a class="search-nav-link" href="#" id="search-nav-link"></a><form action="/search" class="mobile-search" id="mobile-search" method="get"><input class="mobile-search__field" name="q" placeholder="What are you looking for?" type="text" /><button class="mobile-search__icon" type="submit"></button></form></div><div class="main-nav-container__nav2"><nav class="user-actions" id="user-actions"> <ul class="user-actions__list"> <li class="user-actions__signin"> <a class="user-actions__signin-link" href="/user/login">sign in</a> </li> <li class="user-actions__signout"> <a class="user-actions__signout-link" href="/user/logout">Sign Out</a> </li> <li class="user-actions__account"> <a class="user-actions__account-link" href="/user/profile">My Account</a> </li> </ul> </nav> <a class="main-nav-container__subscribe-link" href="/subscriptions">Subscribe</a><div class="quick-search" id="quick-search"><form action="/search" id="quick-search-form" method="GET" name="quick-search" target="_top"><div class="quick-search__wrapper" role="presentation"><input class="quick-search__search-field" id="q" name="q" placeholder="Search" type="text" /><button class="quick-search__button" title="Search" type="submit"></button></div></form></div></div></div></div></header><div class="container"><section class="site-banner" id="site-banner"><div class="site-banner__date">BioWorld - Wednesday, November 27, 2024</div></section><div id="section-2" class="author-show main-body page-authors-show"> <div id="breadcrumbs" class="breadcrumbs"><a class="" href="/">Home</a> » <a class="" href="https://www.bioworld.com/authors">Authors</a> » Lee Landenberger</div> <div class="author-bio"> <div class="detail "> <h1 class="headline author-name"><a href="https://www.bioworld.com/authors/64-lee-landenberger">Lee Landenberger</a></h1> <div class="abstract"></div> <div class="link position"> </div> <div class="link articles"> <a href="https://www.bioworld.com/authors/64-lee-landenberger/articles">Articles</a> </div> </div> </div> <div class="author-tab-list box1"><div class="records articles-list"> <h3 class="feature-title articles-list__title">ARTICLES</h3> <div class="articles-list__row"> <article class="record article-summary "> <div class="image"><a title="Roche snaps up Poseida for $1.5B" class="url" rel="" target="" href="https://www.bioworld.com/articles/714681-roche-snaps-up-poseida-for-15b"><img width="650" height="488" alt="M&A letters over missing puzzle pieces" title="M&A letters over missing puzzle pieces" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/MA-missing-puzzle-pieces.jpg?height=488&t=1714684952&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714681-roche-snaps-up-poseida-for-15b">Roche snaps up Poseida for $1.5B</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 26, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Roche snaps up Poseida for $1.5B" class="more" href="https://www.bioworld.com/articles/714681-roche-snaps-up-poseida-for-15b#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Poseida Therapeutics Inc. is being bought out for $1.5 billion by partner Roche Holdings Inc. to develop allogeneic CAR T therapies to treat hematologic malignancies. The two companies began their collaboration in August 2022, a deal that brought Poseida $110 million up front and another $110 million in near-term milestone payments. With the acquisition, Roche plans to develop CAR T programs for solid tumors and autoimmune diseases with Poseida's genetic engineering platform and preclinical programs.<br /></div><a title="Roche snaps up Poseida for $1.5B" class="more" href="https://www.bioworld.com/articles/714681-roche-snaps-up-poseida-for-15b">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Bridgebio, with FDA approval, faces Pfizer in ATTR" class="url" rel="" target="" href="https://www.bioworld.com/articles/714662-bridgebio-with-fda-approval-faces-pfizer-in-attr"><img width="650" height="488" alt="AI-generated illustration of heart and metabolic impact" title="AI-generated illustration of heart and metabolic impact" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Cardiometabolic-illustration.jpg?height=488&t=1718747319&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714662-bridgebio-with-fda-approval-faces-pfizer-in-attr">Bridgebio, with FDA approval, faces Pfizer in ATTR</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 25, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Bridgebio, with FDA approval, faces Pfizer in ATTR" class="more" href="https://www.bioworld.com/articles/714662-bridgebio-with-fda-approval-faces-pfizer-in-attr#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, small-molecule stabilizer of transthyretin will take on Pfizer Inc.’s Vyndamax (tafamidis, Vyndaqel), a TTR stabilizer approved in 2019 for ATTR-CM but expected to lose exclusivity in late 2028. The approval was based on a phase III study that showed Attruby significantly reduced death and cardiovascular-related hospitalizations. The NDA, which had a Nov. 29 PDUFA date, was approved Nov. 22.<br /></div><a title="Bridgebio, with FDA approval, faces Pfizer in ATTR" class="more" href="https://www.bioworld.com/articles/714662-bridgebio-with-fda-approval-faces-pfizer-in-attr">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="FDA approves biliary tract cancer treatment from Jazz" class="url" rel="" target="" href="https://www.bioworld.com/articles/714623-fda-approves-biliary-tract-cancer-treatment-from-jazz"><img width="650" height="488" alt="Illustration of cancer in the bile ducts" title="Illustration of cancer in the bile ducts" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cholangiocarcinoma-Bile-Duct-Cancer.png?height=488&t=1674573514&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714623-fda-approves-biliary-tract-cancer-treatment-from-jazz">FDA approves biliary tract cancer treatment from Jazz</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 21, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="FDA approves biliary tract cancer treatment from Jazz" class="more" href="https://www.bioworld.com/articles/714623-fda-approves-biliary-tract-cancer-treatment-from-jazz#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">More than a week ahead of its priority PDUFA date, the U.S. FDA has greenlit the first dual HER2-targeted bispecific antibody specifically for previously treated, unresectable or metastatic HER2-positive biliary tract cancer. The approval went to Jazz Pharmaceuticals plc for Ziihera (zanidatamab), an injection given to adults every two weeks. The treatment was designed to have a more favorable profile than competitors, where drugs targeting HER2 such as Astrazeneca plc’s Enhertu (trastuzumab deruxtecan) and Roche Holding AG’s Herceptin (trastuzumab) are options, as well as checkpoint inhibitors such as Merck & Co Inc.’s Keytruda (pembrolizumab).<br /></div><a title="FDA approves biliary tract cancer treatment from Jazz" class="more" href="https://www.bioworld.com/articles/714623-fda-approves-biliary-tract-cancer-treatment-from-jazz">Read More</a> </div> </article> <article class="record article-summary "> <div class="article-summary__details "> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714728-sage-shuts-down-huntingtons-program-after-phase-ii-failure">Sage shuts down Huntington’s program after phase II failure</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 20, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Sage shuts down Huntington’s program after phase II failure" class="more" href="https://www.bioworld.com/articles/714728-sage-shuts-down-huntingtons-program-after-phase-ii-failure#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">The bad news keeps piling up for Sage Therapeutics Inc. Having absorbed other study stumbles in the past few months, the company now has halted development of dalzanemdor in treating Huntington’s disease after top-line phase II data showed it missed a statistically significant difference compared to placebo on the primary endpoint.<br /></div><a title="Sage shuts down Huntington’s program after phase II failure" class="more" href="https://www.bioworld.com/articles/714728-sage-shuts-down-huntingtons-program-after-phase-ii-failure">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Biosion sells antibody rights to Aclaris in $940M deal" class="url" rel="" target="" href="https://www.bioworld.com/articles/714589-biosion-sells-antibody-rights-to-aclaris-in-940m-deal"><img width="650" height="488" alt="Digital handshake " title="Digital handshake " border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Digital-handshake.jpg?height=488&t=1683126686&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714589-biosion-sells-antibody-rights-to-aclaris-in-940m-deal">Biosion sells antibody rights to Aclaris in $940M deal</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 18, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Biosion sells antibody rights to Aclaris in $940M deal" class="more" href="https://www.bioworld.com/articles/714589-biosion-sells-antibody-rights-to-aclaris-in-940m-deal#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Biosion Inc. is getting more than $40 million in cash up front from Aclaris Therapeutics Inc. for the rights to develop two antibodies. The regulatory and sales milestones could also bring Biosion another $900 million. The two assets are BSI-045B, a high affinity and high potency anti-TSLP monoclonal antibody, and BSI-502, a bispecific antibody directed against TSLP and IL4R.<br /></div><a title="Biosion sells antibody rights to Aclaris in $940M deal" class="more" href="https://www.bioworld.com/articles/714589-biosion-sells-antibody-rights-to-aclaris-in-940m-deal">Read More</a> </div> </article> <article class="record article-summary "> <div class="article-summary__details "> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714460-amgen-stock-holds-steady-as-company-dismisses-analyst-report">Amgen stock holds steady as company dismisses analyst report</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 13, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Amgen stock holds steady as company dismisses analyst report" class="more" href="https://www.bioworld.com/articles/714460-amgen-stock-holds-steady-as-company-dismisses-analyst-report#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Amgen Inc. has shrugged off a Cantor Fitzgerald analyst report that wiped about $12 billion from the company’s market cap. The Nov. 12 analyst report noted supplemental data from the company’s phase I study of obesity drug Maritide showing bone mineral density loss in patients.<br /></div><a title="Amgen stock holds steady as company dismisses analyst report" class="more" href="https://www.bioworld.com/articles/714460-amgen-stock-holds-steady-as-company-dismisses-analyst-report">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Flare and Schrödinger join multibillion-dollar collaborations" class="url" rel="" target="" href="https://www.bioworld.com/articles/714446-flare-and-schrodinger-join-multibillion-dollar-collaborations"><img width="650" height="488" alt="Businesspeople shaking hands, meeting with cityscape, charts" title="Businesspeople shaking hands, meeting with cityscape, charts" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Businesspeople-shaking-hands-meeting-with-cityscape-charts.jpg?height=488&t=1718747319&width=650" /></a></div> <div class="article-summary__details has-image"> <div class="kicker article-summary__kicker">Cancer</div> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714446-flare-and-schrodinger-join-multibillion-dollar-collaborations">Flare and Schrödinger join multibillion-dollar collaborations</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 13, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Flare and Schrödinger join multibillion-dollar collaborations" class="more" href="https://www.bioworld.com/articles/714446-flare-and-schrodinger-join-multibillion-dollar-collaborations#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Flare Therapeutics Inc. will receive $70 million in cash up front from Roche Holding AG, and the deal could ultimately bring the company about $1.8 billion plus royalties. Flare will search for small molecules that can be used to treat undruggable transcription factors to treat cancer. Also, Novartis AG will pay computational-chemistry expert Schrödinger Inc. $150 million up front and as much as $2.3 billion in milestones to develop several candidates along with up to $892 million in R&D and milestone payments.<br /></div><a title="Flare and Schrödinger join multibillion-dollar collaborations" class="more" href="https://www.bioworld.com/articles/714446-flare-and-schrodinger-join-multibillion-dollar-collaborations">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Flare and Schrödinger join multibillion-dollar collaborations" class="url" rel="" target="" href="https://www.bioworld.com/articles/714424-flare-and-schrodinger-join-multibillion-dollar-collaborations"><img width="650" height="488" alt="Businesspeople shaking hands, meeting with cityscape, charts" title="Businesspeople shaking hands, meeting with cityscape, charts" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Businesspeople-shaking-hands-meeting-with-cityscape-charts.jpg?height=488&t=1718747319&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714424-flare-and-schrodinger-join-multibillion-dollar-collaborations">Flare and Schrödinger join multibillion-dollar collaborations</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 12, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Flare and Schrödinger join multibillion-dollar collaborations" class="more" href="https://www.bioworld.com/articles/714424-flare-and-schrodinger-join-multibillion-dollar-collaborations#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Flare Therapeutics Inc. will receive $70 million in cash up front from Roche Holding AG, and the deal could ultimately bring the company about $1.8 billion plus royalties. Flare will search for small molecules that can be used to treat undruggable transcription factors to treat cancer. Also, Novartis AG will pay computational-chemistry expert Schrödinger Inc. $150 million up front and as much as $2.3 billion in milestones to develop several candidates along with up to $892 million in R&D and milestone payments.<br /></div><a title="Flare and Schrödinger join multibillion-dollar collaborations" class="more" href="https://www.bioworld.com/articles/714424-flare-and-schrodinger-join-multibillion-dollar-collaborations">Read More</a> </div> </article> <article class="record article-summary "> <div class="article-summary__details "> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714381-rapt-scales-back-after-zelnecirnon-clinical-hold">Rapt scales back after zelnecirnon clinical hold</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 11, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Rapt scales back after zelnecirnon clinical hold" class="more" href="https://www.bioworld.com/articles/714381-rapt-scales-back-after-zelnecirnon-clinical-hold#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Rapt Therapeutics Inc. has decided to shut down its zelnecirnon (RPT-193) program in asthma and atopic dermatitis, causing the company’s stock (NASDAQ:RAPT) to sharply decline Nov. 11. <br /></div><a title="Rapt scales back after zelnecirnon clinical hold" class="more" href="https://www.bioworld.com/articles/714381-rapt-scales-back-after-zelnecirnon-clinical-hold">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Allovir sees a new direction with Kalaris merger" class="url" rel="" target="" href="https://www.bioworld.com/articles/714345-allovir-sees-a-new-direction-with-kalaris-merger"><img width="650" height="488" alt="Connecting puzzle pieces" title="Connecting puzzle pieces" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-puzzle-pieces.png?height=488&t=1588276668&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/714345-allovir-sees-a-new-direction-with-kalaris-merger">Allovir sees a new direction with Kalaris merger</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Nov. 8, 2024</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Allovir sees a new direction with Kalaris merger" class="more" href="https://www.bioworld.com/articles/714345-allovir-sees-a-new-direction-with-kalaris-merger#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Allovir Inc., which has struggled since late last December, will merge with privately held Kalaris Therapeutics Inc. to develop therapies for treating neovascular and exudative retinal diseases. Kalaris already has an anti-VEGF treatment in a phase I study with a data readout set for the third quarter of 2025. Once the deal closes, the combined company name will be Kalaris Therapeutics Inc. and shares will trade on Nasdaq as KLRS. The new company said it plans to drive development of TH-103 for treating neovascular age-related macular degeneration (nAMD), diabetic macular edema and retinal vein occlusion. The phase I study is for treatment of nAMD.<br /></div><a title="Allovir sees a new direction with Kalaris merger" class="more" href="https://www.bioworld.com/articles/714345-allovir-sees-a-new-direction-with-kalaris-merger">Read More</a> </div> </article> </div> <div class="see_all"><a class="next_page" rel="next" href="/authors/64-lee-landenberger/articles?page=2">View All Articles by Lee Landenberger</a></div> </div> </div></div> <aside class="main-interior-sidebar"><div class="main-interior-sidebar__column"><div id="article-recommendations"></div> </div><div class="main-interior-sidebar__column"><section class="popular-stories "> <h1 class="popular-stories__title">Popular Stories</h1><ul class="popular-stories__items"> <li class="popular-stories__item"> <article class="popular-stories__article popular-stories--article"><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/432891-todays-news-in-brief">Today's news in brief</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/84-bioworld">BioWorld</a></div><div class="popular-stories__teaser"><em>BioWorld</em> briefs for Nov. 26, 2024.</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article popular-stories--article"><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/699574-todays-news-in-brief">Today's news in brief</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></div><div class="popular-stories__teaser"><em>BioWorld MedTech</em> briefs for November 26, 2024.</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article -has-image popular-stories--article"><figure class="popular-stories__image"><a class="popular-stories__thumbnail-link" data-eventname="popular-stories" data-eventcategory="click" data-eventaction="popular-stories-image" data-eventlabel="https://www.bioworld.com/articles/714048-j-and-js-ottava-robotic-system-approved-for-us-pivotal-trial" href="https://www.bioworld.com/articles/714048-j-and-js-ottava-robotic-system-approved-for-us-pivotal-trial"><img class="popular-stories__image-thumb" alt="Da Vinci Xi robot - Intuitive Surgical" title="Da Vinci Xi robot - Intuitive Surgical" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/BMT-source/2023/1-26--Da-Vinci-Xi-robot-Intuitive-Surgical.png?height=355&t=1699482891&width=640" /></a></figure><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/714048-j-and-js-ottava-robotic-system-approved-for-us-pivotal-trial">J&J’s Ottava robotic system approved for US pivotal trial</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></div><div class="popular-stories__teaser">Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article -has-image popular-stories--article"><figure class="popular-stories__image"><a class="popular-stories__thumbnail-link" data-eventname="popular-stories" data-eventcategory="click" data-eventaction="popular-stories-image" data-eventlabel="https://www.bioworld.com/articles/714745-in-muscular-dystrophies-gene-therapies-race-the-clock" href="https://www.bioworld.com/articles/714745-in-muscular-dystrophies-gene-therapies-race-the-clock"><img class="popular-stories__image-thumb" alt="Illustration of man holding magnifying glass to human body model showing muscle anatomy" title="Illustration of man holding magnifying glass to human body model showing muscle anatomy" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Muscle-anatomy-dna-research.jpg?height=355&t=1732551219&width=640" /></a></figure><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/714745-in-muscular-dystrophies-gene-therapies-race-the-clock">In muscular dystrophies, gene therapies race the clock</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/84-bioworld">BioWorld</a></div><div class="popular-stories__teaser">Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article -has-image popular-stories--article"><figure class="popular-stories__image"><a class="popular-stories__thumbnail-link" data-eventname="popular-stories" data-eventcategory="click" data-eventaction="popular-stories-image" data-eventlabel="https://www.bioworld.com/articles/714517-evo-ai-can-design-complete-genomes" href="https://www.bioworld.com/articles/714517-evo-ai-can-design-complete-genomes"><img class="popular-stories__image-thumb" alt="DNA on digital background" title="DNA on digital background" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/DNA-on-digital-background.png?height=355&t=1610569805&width=640" /></a></figure><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/714517-evo-ai-can-design-complete-genomes">‘Evo’ AI can design complete genomes </a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/520-bioworld-science">BioWorld Science</a></div><div class="popular-stories__teaser">The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...</div></div></article> </li> </ul> </section></div><div class="main-interior-sidebar__column"><div class="advertisement topics-section-2__col -two"><a href="https://www.bioworld.com/advertising" target="_blank"><img src="https://www.bioworld.com/ext/resources/Ads/2024/bioworld-advertising-reach.jpg" style="width: 300px; height: 250px;"></a></div></div><div class="main-interior-sidebar__column"><div class="topics-cta"><h1 class="topics-cta__headline">BioWorld Premium</h1><div class="topics-cta__teaser"><p>Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.</p></div><a class="topics-cta__link" href="/order">Subscribe</a></div></div></aside></div><footer class="main-footer"><div class="main-footer__top"><nav id="footer-1" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="BioWorld|/topics/84-bioworld" href="/topics/84-bioworld">BioWorld</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Today's news|/topics/84-bioworld" href="/topics/84-bioworld">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Analysis and data insight|/articles/topic/109-analysis-and-data-insight" href="/articles/topic/109-analysis-and-data-insight">Analysis and data insight</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Clinical|/articles/topic/153-clinical" href="/articles/topic/153-clinical">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Data Snapshots|/snapshots" href="/snapshots">Data Snapshots</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Deals and M&A|/articles/topic/214-deals" href="/articles/topic/214-deals">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Financings|/articles/topic/292-financings" href="/articles/topic/292-financings">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Newco news|/articles/topic/391-newco-news" href="/articles/topic/391-newco-news">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Opinion|/blogs/1-bioworld-perspectives" href="/blogs/1-bioworld-perspectives">Opinion</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Regulatory|/articles/topic/402-regulatory" href="/articles/topic/402-regulatory">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Science|/articles/topic/110-bioworld-biome" href="/articles/topic/110-bioworld-biome">Science</a></li></ul></li></ul></div></nav><nav id="footer-2" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="BioWorld MedTech|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">BioWorld MedTech</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Today's news|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Clinical|/articles/topic/153-clinical-bioworld-medtech" href="/articles/topic/153-clinical-bioworld-medtech">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Data Snapshots|/medtech_snapshots" href="/medtech_snapshots">Data Snapshots</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Deals and M&A|/articles/topic/214-deals" href="/articles/topic/214-deals">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Financings|/articles/topic/292-financings-bioworld-medtech" href="/articles/topic/292-financings-bioworld-medtech">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Newco news|/articles/topic/391-newco-news-bioworld-medtech" href="/articles/topic/391-newco-news-bioworld-medtech">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Opinion|/blogs/2-bioworld-medtech-perspectives" href="/blogs/2-bioworld-medtech-perspectives">Opinion</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Regulatory|/articles/topic/402-regulatory-bioworld-medtech" href="/articles/topic/402-regulatory-bioworld-medtech">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Science|/articles/topic/110-bioworld-biome-bioworld-medtech" href="/articles/topic/110-bioworld-biome-bioworld-medtech">Science</a></li></ul></li></ul></div></nav><nav id="footer-3" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="BioWorld Asia|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">BioWorld Asia</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Today's news|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Analysis and data insight|/articles/topic/109-analysis-and-data-insight-bioworld-asia" href="/articles/topic/109-analysis-and-data-insight-bioworld-asia">Analysis and data insight</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Australia|/articles/topic/394-australia-bioworld-asia" href="/articles/topic/394-australia-bioworld-asia">Australia</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="China|/articles/topic/395-china-bioworld-asia" href="/articles/topic/395-china-bioworld-asia">China</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Clinical|/articles/topic/153-clinical-bioworld-asia" href="/articles/topic/153-clinical-bioworld-asia">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Deals and M&A|/articles/topic/214-deals-bioworld-asia" href="/articles/topic/214-deals-bioworld-asia">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Financings|/articles/topic/292-financings-bioworld-asia" href="/articles/topic/292-financings-bioworld-asia">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Newco news|/articles/topic/391-newco-news-bioworld-asia" href="/articles/topic/391-newco-news-bioworld-asia">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Regulatory|/articles/topic/402-regulatory-bioworld-asia" href="/articles/topic/402-regulatory-bioworld-asia">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Science|/articles/topic/110-bioworld-biome-bioworld-asia" href="/articles/topic/110-bioworld-biome-bioworld-asia">Science</a></li></ul></li></ul></div></nav><nav id="footer-5" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="BioWorld Science|/topics/520-bioworld-science" href="/topics/520-bioworld-science">BioWorld Science</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Today's news|/topics/520-bioworld-science" href="/topics/520-bioworld-science">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Biomarkers|/articles/topic/543-biomarkers" href="/articles/topic/543-biomarkers">Biomarkers</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Cancer|/articles/topic/239-cancer" href="/articles/topic/239-cancer">Cancer</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Conferences|/articles/topic/154-conferences" href="/articles/topic/154-conferences">Conferences</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Endocrine/Metabolic|/articles/topic/246-endocrine-metabolic" href="/articles/topic/246-endocrine-metabolic">Endocrine/Metabolic</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Immune|/articles/topic/250-immune" href="/articles/topic/250-immune">Immune</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Infection|/articles/topic/251-infection" href="/articles/topic/251-infection">Infection</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Neurology/Psychiatric|/articles/topic/256-neurology-psychiatric" href="/articles/topic/256-neurology-psychiatric">Neurology/Psychiatric</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Patents|/articles/topic/472-patent" href="/articles/topic/472-patent">Patents</a></li></ul></li></ul></div></nav><nav id="footer-4" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="More|javascript:void(0);" href="javascript:void(0);">More</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="About|/about" href="/about">About</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Advertise with BioWorld|/advertising" href="/advertising">Advertise with BioWorld</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Archives|/newsletters" href="/newsletters">Archives</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Article reprints and permissions|/reprints" href="/reprints">Article reprints and permissions</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Contact us|https://clarivate.com/cortellis/contact-us/" target="_blank" href="https://clarivate.com/cortellis/contact-us/">Contact us</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Cookie policy|https://clarivate.com/legal/cookie-policy/" target="_blank" href="https://clarivate.com/legal/cookie-policy/">Cookie policy</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Copyright notice|https://clarivate.com/legal/copyright-notice/" target="_blank" href="https://clarivate.com/legal/copyright-notice/">Copyright notice</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Data methodology|/content/methodology-chart" href="/content/methodology-chart">Data methodology</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Podcasts|/media/podcasts/532-bioworld-insider-podcast" href="/media/podcasts/532-bioworld-insider-podcast">Podcasts</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Privacy policy|https://clarivate.com/legal/privacy-policy/" target="_blank" href="https://clarivate.com/legal/privacy-policy/">Privacy policy</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Share your news with BioWorld|/share_your_news" href="/share_your_news">Share your news with BioWorld</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Staff|/staff" href="/staff">Staff</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Terms of use|https://clarivate.com/legal/terms-of-use/" target="_blank" href="https://clarivate.com/legal/terms-of-use/">Terms of use</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Topic alerts|/rss" href="/rss">Topic alerts</a></li></ul></li></ul></div></nav></div><div class="main-footer__bottom"><a class="social-media-links" title="Follow us" href="/social-media"><div class="social-media-links__callout">Follow Us</div><div class="social-media-links__twitter"></div> <div class="social-media-links__linkedin"></div></a></div><p class="main-footer__copyright">Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: <a href="http://www.epublishing.com" target="_blank">ePublishing</a><br /><button class="ot-sdk-show-settings" id="ot-sdk-btn" style="margin-top: 1rem">Cookie Settings</button></p></footer></div> <script async="async"> //<![CDATA[ require(['bundle/main.bundle']); //]]> </script> <script src="/javascripts/jquery.rating.pack.js?v=1732722551"></script> </body></html>